In Vitro Diagnostics

Discovering biomarkers that can help improve patient care is a primary goal of Fujifilm. Biomarkers may contribute to the assessment of an individual’s state of health, disease progression, and the response to a particular treatment plan.

Liver cancer

The American Cancer Society estimates that there will be over 40,000 new cases diagnosed and over 30,000 deaths due to liver cancer and intrahepatic bile duct cancer in the United States in 2019*. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide**.

Advances in biomarker research have made it possible to assess the risk for the development of hepatocellular carcinoma (HCC) in patients with chronic liver disease.

HCC surveillance improves patient outcome

Fujifilm is leading the way in generating biomarkers tests associated with various disease types, with a focus on chronic liver disease.

The AFP-L3 (lectin-reactive alphafetoprotein) and DCP (des-gammacarboxy prothrombin) tests are intended to be used as an aid in the risk assessment of patients with chronic liver disease for development of HCC in conjunction with other laboratory findings, imaging studies and clinical assessment. The use of AFP-L3 and DCP tests can aid in the early identification of patients with risk of developing HCC.

Clinical diagnostic and research reagents

Fujifilm also offers in vitro diagnostic reagents and systems that provide users with solutions to address further clinical and research needs. With more than 80 years of experience, Fujifilm provides reagents that deliver results across an area of expertise that includes Non-Esterified Fatty Acid (NEFA) used in the diagnosis of various disorders of lipid metabolism, Total Complement Activity (CH50) used to diagnose abnormalities of complement activities such as lupus and rheumatoid arthritis, HDL Cholesterol and LDL Cholesterol (direct) used to assess the risk of developing coronary heart disease, and Urinary Albumin (microalbumin) used for the early detection of diabetes.

Product Information

HCC Risk Biomarkers

Clinical Diagnostic Reagents

Research Reagents

OEM Opportunities

Contact Us


* Key Statistics About Liver Cancer. American Cancer Society (2019). Retrieved from about/what-is-key-statistics.html

** Hepatocellular Carcinoma: A Review. Journal of Hepatocellular Carcinoma (2016). Retrieved from PMC5063561/